Related Experiment Video
Updated: Aug 7, 2026
10:18
Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Depemokimab-ulaa: A Long-Acting Interleukin-5 Inhibitor
Lauren Linenfelser1, Melissa Lipari1,2, Pramodini Kale-Pradhan1,2
1Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA.
The Annals of Pharmacotherapy
|August 6, 2026
Summary
Depemokimab-ulaa offers a convenient twice-yearly dosing schedule for severe eosinophilic asthma. This interleukin-5 (IL-5) therapy shows comparable efficacy to other IL-5 treatments, improving adherence and clinical outcomes.
Area of Science:
- Pulmonology
- Immunology
- Pharmacology
Background:
- Severe eosinophilic asthma is characterized by elevated eosinophil counts.
- Current treatments include biologics targeting interleukin-5 (IL-5).
- Optimizing treatment adherence and patient outcomes remains a clinical challenge.
Purpose of the Study:
- To review the pharmacology, efficacy, and safety of subcutaneous depemokimab-ulaa.
- To evaluate depemokimab-ulaa as an add-on therapy for severe eosinophilic asthma.
- To compare depemokimab-ulaa with existing anti-IL-5 therapies.
Main Methods:
- Systematic literature search of PubMed, Embase, and ClinicalTrials.gov.
- Inclusion of English-language articles published between January 2020 and March 2026.
- Review focused on pharmacology, safety, efficacy, and clinical trials of depemokimab-ulaa.
Main Results:
- Depemokimab-ulaa demonstrated comparable reductions in blood eosinophil counts in Phase 3 trials (SWIFT-1, SWIFT-2).
- Significantly reduced annualized exacerbation rates compared to placebo (0.46-0.56 vs 1.08-1.11, P < .001).
- Did not meet noninferiority margin when switching from other anti-IL-5 therapies (NIMBLE trial); maintained favorable safety profile.
Conclusions:
- Depemokimab-ulaa provides a convenient twice-yearly dosing option for severe eosinophilic asthma.
- It may serve as an effective alternative to existing anti-IL-5 agents.
- Improved patient adherence and potential for enhanced clinical outcomes are key advantages.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...